Literature DB >> 28170133

Optimal strategies for the diagnosis of community-onset diarrhea in solid organ transplant recipients: Less is more.

Sonya A Trinh1, Ignacio A Echenique2, Sudhir Penugonda1, Michael P Angarone1.   

Abstract

BACKGROUND: Diarrhea, a common complication after solid organ transplant (SOT), is associated with allograft failure and death. No evidence-based guidelines exist for the evaluation of diarrhea in SOT recipients. We performed a cost analysis to derive a testing algorithm for the diagnosis of community-onset diarrhea that minimizes costs without compromising diagnostic yields.
DESIGN: A cost analysis was performed on a retrospective cohort of 422 SOT admissions for community-onset diarrhea over an 18-month period. A stepwise testing model was applied on a population level to assess test costs relative to diagnostic yields.
RESULTS: Over an 18-month period, 1564 diagnostic tests were performed and 127 (8.1%) returned positive. Diagnostic testing accounted for $95 625 of hospital costs. The tests with the lowest cost per decrease in the false-omission rate (FOR) were stool Clostridium difficile polymerase chain reaction (PCR) ($156), serum cytomegalovirus quantitative PCR ($1529), stool norovirus (NV) PCR ($4673), and stool culture ($6804). A time-to-event analysis found no significant difference in the length of hospital stay between patients with and without NV testing (P=.520).
CONCLUSIONS: A stepwise testing strategy can reduce costs without compromising diagnostic yields. In the first-stage testing, we recommend assessment for C. difficile, cytomegalovirus, and food-borne bacterial pathogens. For persistent diarrheal episodes, second-stage evaluation should include stool NV PCR, Giardia/Cryptosporidium enzyme immunoassay, stool ova and parasite, reductions in immunosuppressive therapy, and possibly endoscopy. Although NV testing had a relatively low cost per FOR, we recommend NV testing during second-stage evaluation, as an NV diagnosis may not lead to changes in clinical management or further reductions in length of hospital stay.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Clostridium difficilezzm321990; cost analysis; cytomegalovirus; diarrhea; norovirus; solid organ transplant

Mesh:

Year:  2017        PMID: 28170133      PMCID: PMC5382062          DOI: 10.1111/tid.12673

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  14 in total

1.  Severe diarrhea in renal transplant patients: results of the DIDACT study.

Authors:  B Maes; K Hadaya; B de Moor; P Cambier; P Peeters; J de Meester; J Donck; J Sennesael; J-P Squifflet
Journal:  Am J Transplant       Date:  2006-06       Impact factor: 8.086

2.  Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients.

Authors:  Christine M Durand; Kieren A Marr; Christina A Arnold; Lydia Tang; Daniel J Durand; Robin K Avery; Alexandra Valsamakis; Dionissios Neofytos
Journal:  Clin Infect Dis       Date:  2013-08-15       Impact factor: 9.079

3.  Utility of colonoscopy in the evaluation of diarrhea in solid organ transplant recipients.

Authors:  John P Rice; Bret J Spier; Daniel D Cornett; Andrew J Walker; Kelly Richie; Patrick R Pfau
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

4.  Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea.

Authors:  Damien Roos-Weil; Katia Ambert-Balay; Fanny Lanternier; Marie-France Mamzer-Bruneel; Dominique Nochy; Pierre Pothier; Véronique Avettand-Fenoel; Dany Anglicheau; Renaud Snanoudj; Lynda Bererhi; Eric Thervet; Marc Lecuit; Christophe Legendre; Olivier Lortholary; Julien Zuber
Journal:  Transplantation       Date:  2011-07-15       Impact factor: 4.939

5.  A cost benefit analysis of the Luminex xTAG Gastrointestinal Pathogen Panel for detection of infectious gastroenteritis in hospitalised patients.

Authors:  Simon D Goldenberg; Mariana Bacelar; Peter Brazier; Karen Bisnauthsing; Jonathan D Edgeworth
Journal:  J Infect       Date:  2014-11-29       Impact factor: 6.072

6.  Diagnostic yields in solid organ transplant recipients admitted with diarrhea.

Authors:  Ignacio A Echenique; Sudhir Penugonda; Valentina Stosor; Michael G Ison; Michael P Angarone
Journal:  Clin Infect Dis       Date:  2014-11-03       Impact factor: 9.079

7.  Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation.

Authors:  H Weclawiak; A Ould-Mohamed; B Bournet; C Guilbeau-Frugier; F Fortenfant; F Muscari; F Sallusto; C Dambrin; L Esposito; J Guitard; M Abbal; L Rostaing; N Kamar
Journal:  Am J Transplant       Date:  2011-02-07       Impact factor: 8.086

8.  Diarrhoea following renal transplantation.

Authors:  Mehmet Riza Altiparmak; Sinan Trablus; Omer Nuri Pamuk; Süheyla Apaydin; Muzaffer Sariyar; Recep Oztürk; Rezzan Ataman; Kamil Serdengeçti; Ekrem Erek
Journal:  Clin Transplant       Date:  2002-06       Impact factor: 2.863

9.  Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.

Authors:  Christopher R Polage; Clare E Gyorke; Michael A Kennedy; Jhansi L Leslie; David L Chin; Susan Wang; Hien H Nguyen; Bin Huang; Yi-Wei Tang; Lenora W Lee; Kyoungmi Kim; Sandra Taylor; Patrick S Romano; Edward A Panacek; Parker B Goodell; Jay V Solnick; Stuart H Cohen
Journal:  JAMA Intern Med       Date:  2015-11       Impact factor: 21.873

Review 10.  Diarrhea after kidney transplantation: a new look at a frequent symptom.

Authors:  Florence Aulagnon; Anne Scemla; Susan DeWolf; Christophe Legendre; Julien Zuber
Journal:  Transplantation       Date:  2014-10-27       Impact factor: 4.939

View more
  2 in total

Review 1.  Molecular Diagnostic Advances in Transplant Infectious Diseases.

Authors:  Brittany A Young; Kimberly E Hanson; Carlos A Gomez
Journal:  Curr Infect Dis Rep       Date:  2019-11-26       Impact factor: 3.725

2. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.